Juno Therapeutics Inc Backtested Returns
Macroaxis considers Juno Therapeutics to be not very risky. Juno Therapeutics Inc
holds Efficiency (Sharpe) Ratio of -0.0953 which attests that Juno Therapeutics Inc
had -0.0953% of return per unit of risk over the last 1 month. Macroaxis philosophy towards determining risk of any stock is to look at both systematic and un-systematic factors of the business, including all available market data and technical indicators
. Juno Therapeutics Inc exposes twenty-one different technical indicators
which can help you to evaluate volatility that cannot be diversified away. Please be advised to check out Juno Therapeutics Market Risk Adjusted Performance
of 0.2892 and Risk Adjusted Performance
of (0.05557) to validate risk estimate we provide. Macroaxis gives Juno Therapeutics performance score of 0 on a scale of 0 to 100. The company retains Market Volatility (i.e. Beta) of -2.322 which attests that as returns on market increase, returns on owning Juno Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Juno Therapeutics is expected to significantly outperform it.. Even though it is essential to pay attention to Juno Therapeutics Inc current price history, it is always good to be careful when utilizing equity current price movements. Macroaxis philosophy towards determining future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Juno Therapeutics Inc exposes twenty-one different technical indicators which can help you to evaluate its performance. Juno Therapeutics Inc has expected return of -0.4608%. Please be advised to check out Juno Therapeutics Standard Deviation, Maximum Drawdown as well as the relationship between Maximum Drawdown and Expected Short fall to decide if Juno Therapeutics Inc past performance will be repeated at some point in the near future.
|15 days auto-correlation|| 0.43 |
Juno Therapeutics Inc has average predictability. Overlapping area represents the amount of predictability between Juno Therapeutics time series from November 14, 2017 to November 29, 2017 and November 29, 2017 to December 14, 2017. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Juno Therapeutics Inc price movement. The serial correlation of 0.43 indicates that just about 43.0% of current Juno Therapeutics price fluctuation can be explain by its past prices.
|Correlation Coefficient|| 0.43|
|Spearman Rank Test|| 0.09|
|Price Variance|| 14.5|
|Lagged Price Variance|| 6.72|
Juno Therapeutics Lagged Returns